Study for using the healed novel coronavirus pneumonia (COVID-19) patients plasma in the treatment of severe critical cases

Study on the application of convalescent plasma therapy in severe COVID-19

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030627

Enrollment

Unknown

Registered

2020-03-08

Start date

2020-02-01

Completion date

Unknown

Last updated

2020-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Control group:routine treatment

Experimental group:Convalescent plasma therapy + routine treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed as COVID-19 by nucleic acid test and were in accordance with the clinical classification of severe or critically illness. (refer to the clinical classification criteria in the pneumonia diagnosis and treatment program of novel coronavirus infection, General Office of the National Health Commission (trial version 4)).

Exclusion criteria

Exclusion criteria: Patients with hypersensitivity to plasma products; patients with severe transfusion reactions in the past; patients with acute pulmonary edema, congestive heart failure, pulmonary embolism, malignant hypertension, polycythemia vera, extreme renal failure and other diseases.

Design outcomes

Primary

Measure	Time frame
Tempreture;Virus nucleic acid detection;	—

Secondary

Measure	Time frame
Laboratory examination;Length of admission;Mortality rate;Incidence of adverse events in blood transfusion;	—

Countries

China

Contacts

Public ContactGuojun Zhang

The First Affiliated Hospital of Zhengzhou University

zlgj-001@126.com+86 13673665268

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026